Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations (Q38152742)

29 August 2017

Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations (English)

1 reference

29 August 2017

1

Nadia Harbeck

0 references

author name string

Rachel Wuerstlein

series ordinal

2

1 reference

29 August 2017

1 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

73

1 reference

29 August 2017

15

1 reference

29 August 2017

1665-1680

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0118-z

29 August 2017

0 references

cites work

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

St. Gallen 2011: Summary of the Consensus Discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Optimizing the management of HER2-positive early breast cancer: the clinical reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Metastatic behavior of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

ABC1 Consensus Conference - a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Trends and Novel Approaches in Neoadjuvant Treatment of Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Docetaxel combined with targeted therapies in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Dual HER2-targeted approaches in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic ana

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Neratinib (HKI-272) in the treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

1st International consensus guidelines for advanced breast cancer (ABC 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0118-Z

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

12 December 2020

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

12 December 2020

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

1 reference

12 December 2020

Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer

1 reference

12 December 2020

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

1 reference

12 December 2020

Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

1 reference

12 December 2020

Trastuzumab administration associated with change in HER2 status

1 reference

12 December 2020

HER2 as a predictor of therapeutic response in breast cancer

1 reference

12 December 2020

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

12 December 2020

Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic br

1 reference

12 December 2020

BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors.

1 reference

12 December 2020

10.1007/S40265-013-0118-Z

Identifiers

DOI

1 reference

PubMed ID

24127221

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

24127221